The following is an abstract for the selected article. A PDF download of the full text of this article is available here. Members may download full texts at no charge. Non-members may be charged a small fee for certain articles.
Early Diagnosis of Prostate Cancer by Citrate Determination in Urine with Europium–Oxytetracycline Complex
Volume 66, Number 8 (Aug. 2012) Page 958-961
FLÁVIA R. O. SILVA, CAMILA T. NABESHIMA, MARIA H. BELLINI, and LILIA C. COURROL*
Normal prostate tissue contains high levels of citrate. In the presence of prostate cancer, the citrate level is diminished. In this paper we show that it is possible to use europium–oxytetracycline complex as a citrate fluorescent probe and consequently as a prostate cancer probe. We analyzed normal nude male mice urine and urine from nude male mice in which prostate cancer was induced by intraprostatic inoculation of DU145 cells. The urine samples were collected from the animals at the 7th, 14th, 21st, and 35th days after the surgery procedures. The intensity of europium emission at 615 nm in europium–oxytetracycline complex in the presence of citrate increases linearly. The citrate concentrations were determined from a calculated calibration curve. A concentration decrease in malignant prostate urine from the normal (PBS group) urine value from ∼8.0 mM to ∼2.4 mM (tumor group at 35th day) was found. The obtained results indicated that europium–oxytetracycline provides a significant biomarker for prostate cancer detection with a direct, accurate, noninvasive, and non-enzymatic method for measurement of citrate in biological fluids.
Index Headings: Citrate; Europium; Tetracycline; Fluorescence; Fluorescent probe; Prostate cancer.